Leeds In Vitro Diagnostics Co-operative

NIHR Leeds MIC Launched!

16 April 2018

NIHR Leeds In Vitro Diagnostics Co-operative (NIHR Leeds MIC) held its official launch event on 7 March 2018. Our audience included MIC theme leads, academics, industry partners and members of our Patient and Public Involvement and Engagement group who joined us to discuss the future of NIHR Leeds MIC and current opportunities within the sector.

Sir Alan Langlands (Vice-Chancellor, University of Leeds) and Julian Hartley (Chief Executive, Leeds Teaching Hospitals NHS Trust) opened the event with a talk on innovation at Leeds. This was followed by a presentation from Professor Gordon Cook (Clinical Director, NIHR MIC Leeds) and Dr Michael Messenger (Deputy Director, NIHR Leeds MIC) who set out the key aims of the MIC and looked back at the success of its predecessor, the NIHR Diagnostic Evidence Co-operative Leeds.

We were also delighted to welcome Doris-Ann Williams MBE, Chief Executive of the British In Vitro Diagnostics Association (BIVDA), to give an overview of the current regulatory landscape for IVDs and offer some insights into how this will change over the next few years with the launch of the new IVD Regulation in May 2017.

Dr Helen Radford, NIHR Leeds MIC Operational Director, said: “This was a fantastic opportunity to showcase the NIHR Leeds MIC strengths and expertise to a wide audience. Doris-Ann's talk, in particular, was really well received and helpful in setting out the tasks ahead of us.”

Several of NIHR MIC Leeds’ theme leads and key partners were also able to offer their expert views on effective evaluation and implementation of novel IVDs.

NIHR Leeds MIC partner organisations, including Leeds Centre for Personalised Medicine and Health, Nexus, Leeds Industry Engagement Academy and NIHR@Leeds Infrastructure exhibited during the event, showcasing Leeds’ capabilities at supporting IVD and Medtech innovation in the region.

“The UK has a tremendous opportunity to be a world leader in the field of in vitro diagnostic devices,” says Professor Cook “It was clear at our launch event that there is huge commitment to driving forward new advances in this field. We’re very excited to be working with our clinical and industry partners to accelerate clinical adoption of the most effective IVDs.”

We’re particularly grateful to our sponsors: Genomic Health, Myriad, Roche, and Siemens Healthineers for their support of the event.

Feedback from the day was extremely positive: delegates appreciated the opportunity to network with the Leeds MIC team and offered valuable insights into new themes such as infection diagnostics and multi-disciplinary pathology.